Cécile Chartier
Director/Miembro de la Junta en CELLECTIS S.A. .
Cargos activos de Cécile Chartier
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
CELLECTIS S.A. | Director/Miembro de la Junta | 27/06/2023 | - |
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Director Técnico/Científico/I+D | - | - |
Historial de carrera de Cécile Chartier
Formación de Cécile Chartier.
Universite Louis Pasteur Strasbourg I | Doctorate Degree |
Estadísticas
Internacional
Francia | 3 |
Estados Unidos | 2 |
Operativa
Director/Board Member | 1 |
Doctorate Degree | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectorial
Health Technology | 2 |
Consumer Services | 2 |
Technology Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
CELLECTIS S.A. | Health Technology |
Empresas privadas | 1 |
---|---|
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Technology Services |
- Bolsa de valores
- Insiders
- Cécile Chartier
- Experiencia